People
Find researchers
Who has published, run trials or held grants on a topic, and how to reach them through people they have worked with.
Ranked by expertise@1: every paper, trial or grant they worked on in scope counts, recent work counts more, and being first or last author or a trial’s principal investigator counts 1.5 times.
Researchers with CLDN18.2 work
238 researchers in CLDN18.2, best first; 51–75 shown.
- Younis Al-Mufargi · Medical City for Military and Security Services
In CLDN18.2: 1 paper. Expertise score 1.50. 1 paper in all, 2026.
Topics: CLDN18.2, All pancreatic cancer
- Hua Jiang
In CLDN18.2: 2 papers. Expertise score 1.46. 7 papers in all, 2012–2025.
Topics: All pancreatic cancer, CLDN18.2, KRAS
- Fang Xieprovisional identity · Huashan Hospital
In CLDN18.2: 1 trial. Expertise score 1.38. 2 trials in all, 2023.
Topics: All pancreatic cancer, CLDN18.2
- Ph.D Xianjun Yuprovisional identity · Fudan University
In CLDN18.2: 1 trial. Expertise score 1.38. 1 trial in all, 2023.
Topics: CLDN18.2, All pancreatic cancer
- Changsong Qi · Peking University Cancer Hospital
In CLDN18.2: 2 papers. Expertise score 1.34. 2 papers in all, 2023–2024.
Topics: CLDN18.2, All pancreatic cancer
- Hongkai Zhang
In CLDN18.2: 2 papers. Expertise score 1.34. 7 papers in all, 2021–2025.
Topics: All pancreatic cancer, CLDN18.2
- Jun Zhou
In CLDN18.2: 2 papers. Expertise score 1.34. 7 papers in all, 2016–2024.
Topics: All pancreatic cancer, CLDN18.2, Early detection
- Andrew Winer · SUNY Downstate Health Sciences University
In CLDN18.2: 1 paper. Expertise score 1.27. 1 paper in all, 2025.
Topics: CLDN18.2, KRAS, All pancreatic cancer
- Anwaar Saeed · University of Pittsburgh Medical Center
In CLDN18.2: 1 paper. Expertise score 1.27. 12 papers, 2 trials in all, 2020–2026.
Topics: All pancreatic cancer, KRAS, CLDN18.2, KRAS G12D
- Eden Demere Amare
In CLDN18.2: 1 paper. Expertise score 1.27. 2 papers in all, 2025.
Topics: All pancreatic cancer, CLDN18.2
- Erica S. Tsang · Princess Margaret Cancer Centre
In CLDN18.2: 1 paper. Expertise score 1.27. 21 papers, 3 trials in all, 2019–2026.
Topics: All pancreatic cancer, KRAS, CLDN18.2, Early detection
- Graziana Arborea · Gastroenterology Hospital "Saverio de Bellis"
In CLDN18.2: 1 paper. Expertise score 1.27. 2 papers in all, 2022–2025.
Topics: All pancreatic cancer, CLDN18.2
- Huichuan Zhao · Yangtze University
In CLDN18.2: 1 paper. Expertise score 1.27. 1 paper in all, 2025.
Topics: CLDN18.2, All pancreatic cancer
- Hyunsung Kim · Hanyang University
In CLDN18.2: 1 paper. Expertise score 1.27. 2 papers in all, 2025.
Topics: All pancreatic cancer, CLDN18.2
- Li J. Yu
In CLDN18.2: 1 paper. Expertise score 1.27. 1 paper in all, 2025.
Topics: CLDN18.2, All pancreatic cancer
- Raffaele Armentano · Gastroenterology Hospital "Saverio de Bellis"
In CLDN18.2: 1 paper. Expertise score 1.27. 2 papers in all, 2025–2026.
Topics: All pancreatic cancer, CLDN18.2
- Songbing Qin · First Affiliated Hospital of Soochow University
In CLDN18.2: 1 paper. Expertise score 1.27. 3 papers in all, 2025.
Topics: All pancreatic cancer, CLDN18.2
- Thomas Arnason
In CLDN18.2: 1 paper. Expertise score 1.27. 6 papers in all, 2022–2026.
Topics: All pancreatic cancer, CLDN18.2
- Xiaoli Lan
In CLDN18.2: 1 trial. Expertise score 1.27. 5 papers, 5 trials in all, 2020–2026.
Topics: All pancreatic cancer, CLDN18.2
- Yunfeng Feng
In CLDN18.2: 1 paper. Expertise score 1.27. 1 paper in all, 2025.
Topics: CLDN18.2, All pancreatic cancer
- Ruixin Sun
In CLDN18.2: 2 papers. Expertise score 1.23. 2 papers in all, 2023.
Topics: CLDN18.2, All pancreatic cancer
- Yifan Liu
In CLDN18.2: 2 papers. Expertise score 1.23. 2 papers in all, 2023.
Topics: CLDN18.2, All pancreatic cancer
- Lin Shenprovisional identity · Department of GI Oncology, Peking University Cancer Hospita
In CLDN18.2: 1 trial. Expertise score 1.17. 1 trial in all, 2022.
Topics: CLDN18.2, All pancreatic cancer
- Luo Tianhangprovisional identity · Changhai Hospital
In CLDN18.2: 1 trial. Expertise score 1.17. 1 trial in all, 2022.
Topics: CLDN18.2, All pancreatic cancer
- M.D., Ph.D. Josep Taberneroprovisional identity · Vall d'Hebron University Hospital (HUVH)
In CLDN18.2: 1 trial. Expertise score 1.17. 1 trial in all, 2022.
Topics: CLDN18.2, All pancreatic cancer